Citation Impact
Citing Papers
Claudin-7 Regulates EpCAM-Mediated Functions in Tumor Progression
2009
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
MicroRNA-155 is induced during the macrophage inflammatory response
2007 StandoutNobel
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
2009 Standout
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
2004
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
2015 StandoutNobel
Treatment of kidney cancer
2009 StandoutNobel
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis
2013
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
2005 StandoutNobel
Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage
2008 StandoutNobel
The role of cytoreductive nephrectomy in the era of molecular targeted therapy
2009
Molecular imaging in drug development
2008 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Ferroptosis: Death by Lipid Peroxidation
2015 Standout
Polymeric Structure and Host Toll-like Receptor 4 Dictate Immunogenicity of NY-ESO-1 Antigen in Vivo
2011
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
2003
A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion
2007
Renal Cell Carcinoma Guideline
2007
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
The PD-1–PD-L pathway in immunological tolerance
2006 StandoutNobel
Comparison of cryoablation, radiofrequency ablation and high‐intensity focused ultrasound for treating small renal tumours
2005
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Prognostic relevance of the mTOR pathway in renal cell carcinoma
2007
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Future strategies in the diagnosis, staging and treatment of bladder cancer
2003
Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
2014
Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience
2007
Cytokine patterns in patients with cancer: a systematic review
2013 Standout
Clinical molecular imaging with positron emission tomography
2006
Novel approaches in the therapy of metastatic renal cell carcinoma
2005
Image-Guided Percutaneous Cryoablation of Renal Tumors
2007
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
A Review of Integrated Staging Systems for Renal Cell Carcinoma
2012
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Bosniak Category IIF and III Cystic Renal Lesions: Outcomes and Associations
2011
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Checkpoint Blockade in Cancer Immunotherapy
2006 StandoutNobel
Dysregulated pH: a perfect storm for cancer progression
2011 Standout
Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881
2008
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
2011
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
2016 Standout
Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?
2006
A Preoperative Prognostic Model for Patients Treated with Nephrectomy for Renal Cell Carcinoma
2008
Renal Function After Nephron-sparing Surgery Versus Radical Nephrectomy: Results from EORTC Randomized Trial 30904
2013
Renal cell carcinoma
2017 Standout
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy
2005
Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases
2012 Standout
Modulation of carbonic anhydrase activity and its applications in therapy
2004
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
2012 Standout
How To Build and Interpret a Nomogram for Cancer Prognosis
2008 Standout
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
2006
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
The Chromophobe Tumor Grading System is the Preferred Grading Scheme for Chromophobe Renal Cell Carcinoma
2011
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
2005
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
2004
REVIEW OF METAL, CARBON AND POLYMER NANOPARTICLES FOR INFRARED PHOTOTHERMAL THERAPY
2013
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
2003
Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases
2005
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Gene Signatures of Progression and Metastasis in Renal Cell Cancer
2005
Anticancer effect of lysine, proline, arginine, ascorbic acid and green tea extract on human renal adenocarcinoma line 786-0
2006
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
2016
Multi-Institutional Validation of a New Renal Cancer–Specific Survival Nomogram
2007
Cancer treatment and survivorship statistics, 2016
2016 Standout
The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth
2009 Standout
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
2003
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes
2013
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Cancer treatment and survivorship statistics, 2019
2019 Standout
Independent Validation of the 2010 American Joint Committee on Cancer TNM Classification for Renal Cell Carcinoma: Results From a Large, Single Institution Cohort
2011
Renal cell carcinoma as a cause of iron deficiency anemia
2014
Tumor‐associated Carbonic Anhydrases and Their Clinical Significance
2006
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Claudins and the Modulation of Tight Junction Permeability
2013 Standout
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
2014 Standout
Guideline for Management of the Clinical T1 Renal Mass
2009 Standout
RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY
2005
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
2004
Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
2009
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of Ken‐ryu Han being referenced
Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma
2003
Pathobiology and prognosis of chromophobe renal cell carcinoma
2008
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
2003
Renal cell carcinoma with retroperitoneal lymph nodes
2003
Prognostic factors and molecular markers for renal cell carcinoma
2001
Cystic renal cell carcinoma: Biology and clinical behavior
2004
Prognostic Significance of Venous Thrombus in Renal Cell Carcinoma. Are Renal Vein and Inferior Vena Cava Involvement Different?
2004
URETEROENTERIC ANASTOMOSIS IN CONTINENT URINARY DIVERSION: LONG-TERM RESULTS AND COMPLICATIONS OF DIRECT VERSUS NONREFLUXING TECHNIQUES
2000
EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS PREDICTS BONE METASTASIS IN PATIENTS PRESENTING WITH RENAL CELL CARCINOMA: IMPLICATION FOR PREOPERATIVE BONE SCANS
2004
Renal Cell Carcinoma With Retroperitoneal Lymph Nodes: Role of Lymph Node Dissection
2003
THE EFFECTS OF INTENTIONAL CRYOABLATION AND RADIO FREQUENCY ABLATION OF RENAL TISSUE INVOLVING THE COLLECTING SYSTEM IN A PORCINE MODEL
2005
Cachexia-Like Symptoms Predict a Worse Prognosis in Localized T1 Renal Cell Carcinoma.
2004
Epithelial Cell Adhesion Molecule (KSA) Expression
2004
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
2003
TNM T3a Renal Cell Carcinoma: Adrenal Gland Involvement is Not the Same as Renal Fat Invasion
2003
Positron Emission Tomography in Urologic Oncology
2002
Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis
2003
Validation of an Integrated Staging System Toward Improved Prognostication of Patients With Localized Renal Cell Carcinoma in an International Population
2003
PROGNOSTIC VALUE OF CARBONIC ANHYDRASE IX AND KI67 AS PREDICTORS OF SURVIVAL FOR RENAL CLEAR CELL CARCINOMA
2004
Prostate Stem Cell Antigen Expression is Associated With Gleason Score, Seminal Vesicle Invasion and Capsular Invasion in Prostate Cancer
2004